Disease-induced neuroinflammation and depression

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 4, 2016, Pages 414-433

  Benatti, Cristina ^a   Blom, Joan M C ^a   Rigillo, Giovanna ^a   Alboni, Silvia ^a   Zizzi, Francesca ^b   Torta, Riccardo ^b   Brunello, Nicoletta ^a   Tascedda, Fabio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Allostasis; Blood brain barrier permeability; Chronic pain; Depression; Diabetes mellitus; Human immunodeficiency virus infection; Inflammasome; Microglia; Neuroinflammation; Pro inflammatory cytokines; Stroke; Tryptophan catabolites

Indexed keywords

CRYOPYRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTICLE; BLOOD BRAIN BARRIER; CELL INFILTRATION; CELL MEMBRANE PERMEABILITY; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; CYTOKINE PRODUCTION; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; BIBLIOGRAPHIC DATABASE; COMPLICATION; ENCEPHALITIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

BLOOD-BRAIN BARRIER; CHRONIC PAIN; CYTOKINES; DATABASES, BIBLIOGRAPHIC; DEPRESSION; DIABETES MELLITUS; ENCEPHALITIS; HIV INFECTIONS; HUMANS; INFLAMMASOMES; MICROGLIA; STROKE;

EID: 84964048196     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160321104749     Document Type: Article

References (278)

1. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31(9): 464-8.
2. Ogłodek E, Szota A, Just M, Moś D, Araszkiewicz A. The role of the neuroendocrine and immune systems in the pathogenesis of depression. Pharmacol Rep 2014; 66(5): 776-81.
3. Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 2015; Epub ahead of print.
4. Sterling P. Allostasis: a model of predictive regulation. Physiol Behav 2012; 106(1): 5-15.
5. Peters A, McEwen BS. Introduction for the allostatic load special issue. Physiol Behav 2012; 106(1): 1-4.
6. Karatsoreos IN, McEwen BS. Resilience and vulnerability: a neurobiological perspective. F1000Prime Rep 2013; 5: 13.
7. Mansur RB, Brietzke E, McIntyre RS. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev 2015; 52: 89-104.
8. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009; 7(4): 357-63.
9. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006; 68(2): 262-8.
10. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke 2013; 44(4): 1105-10.
11. Dubé B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci 2005; 30(4): 237-46.
12. O’Connor JC, Johnson DR, Freund GG. Psychoneuroimmune implications of type 2 diabetes. Neurol Clin 2006; 24(3): 539-59.
13. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58(3): 175-89.
14. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression’s multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32(1): 7-24.
15. McEwen BS, Gianaros PJ. Stress- and allostasis-induced brain plasticity. Annu Rev Med 2011; 62: 431-45.
16. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37(1): 13-25.
17. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32(7): 1139-51.
18. da Fonseca AC, Matias D, Garcia C, et al. The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 2014; 8: 362.
19. Abbott NJ, Friedman A. Overview and introduction: the bloodbrain barrier in health and disease. Epilepsia 2012; 53(Suppl 6): 1-6.
20. Delpech JC, Madore C, Nadjar A, Joffre C, Wohleb ES, Layé S. Microglia in neuronal plasticity: Influence of stress. Neuropharmacology 2015; 96(Pt A): 19-28.
21. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014; 141(3): 314-27.
22. Estes ML, McAllister AK. Alterations in immune cells and mediators in the brain: it’s not always neuroinflammation. Brain Pathol 2014; 24(6): 623-30.
23. Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets 2014; 13(10): 1654-66.
24. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 722-9.
25. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013; 31: 105-14.
26. Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci 2014; 8: 315.
27. Alboni S, Gibellini L, Montanari C, et al. N-acetyl-cysteine prevents toxic oxidative effects induced by IFN-α in human neurons. Int J Neuropsychopharmacol 2013; 2013: 1-17.
28. Campbell BM, Charych E, Lee AW, Möller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci 2014; 8: 12.
29. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65(9): 732-41.
30. Anderson G, Maes M, Berk M. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol 2012; 88: 27-48.
31. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT’ hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
32. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011; 130(2): 226-38.
33. Hurley LL, Tizabi Y. Neuroinflammation, neurodegeneration, and depression. Neurotox Res 2013; 23(2): 131-44.
34. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6(7): e1000100.
35. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
36. Zunszain PA, Hepgul N, Pariante CM. Inflammation and Depression. Curr Top Behav Neurosci 2013; 14: 135-51.
37. Hackett ML, Köhler S, O’Brien JT, Mead GE. Neuropsychiatric outcomes of stroke. Lancet Neurol 2014; 13(5): 525-34.
38. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007; 6(2): 182-7.
39. Murray KN, Buggey HF, Denes A, Allan SM. Systemic immune activation shapes stroke outcome. Mol Cell Neurosci 2013; 53: 14-25.
40. Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A, Licata G. Inflammation in ischemic stroke subtypes. Curr Pharm Des 2012; 18(28): 4289-310.
41. Kim JY, Kawabori M, Yenari MA. Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem 2014; 21(18): 2076-97.
42. Siniscalchi A, Gallelli L, De Sarro G, Malferrari G, Santangelo E. Antiepileptic drugs for central post-stroke pain management. Pharmacol Res 2012; 65(2): 171-5.
43. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. Stroke 2005; 36(10): 2296-301.
44. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V, Group DS. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol 2006; 253(5): 556-62.
45. Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry 2013; 202(1): 14-21.
46. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005; 36(6): 1330-40.
47. Provinciali L, Paolucci S, Torta R, Toso V, Gobbi B, Gandolfo C. Depression after first-ever ischemic stroke: the prognostic role of neuroanatomic subtypes in clinical practice. Cerebrovasc Dis 2008; 26(6): 592-9.
48. Hellmann-Regen J, Piber D, Hinkelmann K, et al. Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263(Suppl 2): S123-36.
49. Loubinoux I, Kronenberg G, Endres M, et al. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 2012; 16(9): 1961-9.
50. Li W, Ling S, Yang Y, Hu Z, Davies H, Fang M. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol Lett 2014; 35(2): 104-9.
51. Spalletta G, Bossù P, Ciaramella A, Bria P, Caltagirone C, Robinson RG. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol Psychiatry 2006; 11(11): 984-91.
52. Zehendner CM, White R, Hedrich J, Luhmann HJ. A neurovascular blood-brain barrier in vitro model. Methods Mol Biol 2014; 1135: 403-13.
53. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis 2008; 32(2): 200-19.
54. Fang W, Sha L, Kodithuwakku ND, et al. Attenuated Blood-Brain Barrier Dysfunction by XQ-1H Following Ischemic Stroke in Hyperlipidemic Rats. Mol Neurobiol 2014; 52(1): 162-75.
55. Bake S, Selvamani A, Cherry J, Sohrabji F. Blood brain barrier and neuroinflammation are critical targets of IGF-1-mediated neuroprotection in stroke for middle-aged female rats. PLoS One 2014; 9(3): e91427.
56. Liu Y, Tang G, Li Y, et al. Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation 2014; 11: 177.
57. Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Curr Pharm Des 2012; 18(25): 3670-6.
58. Grønberg NV, Johansen FF, Kristiansen U, Hasseldam H. Leukocyte infiltration in experimental stroke. J Neuroinflammation 2013; 10: 115.
59. Lehmann J, Härtig W, Seidel A, et al. Inflammatory cell recruitment after experimental thromboembolic stroke in rats. Neuroscience 2014; 279: 139-54.
60. Easton AS. Neutrophils and stroke - can neutrophils mitigate disease in the central nervous system? Int Immunopharmacol 2013; 17(4): 1218-25.
61. Urra X, Cervera A, Villamor N, Planas AM, Chamorro A. Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience 2009; 158(3): 1174-83.
62. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006; 26(5): 605-12.
63. Wang J, Yang Z, Liu C, Zhao Y, Chen Y. Activated microglia provide a neuroprotective role by balancing glial cell-line derived neurotrophic factor and tumor necrosis factor-α secretion after subacute cerebral ischemia. Int J Mol Med 2013; 31(1): 172-8.
64. Wohleb ES, McKim DB, Sheridan JF, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front Neurosci 2014; 8: 447.
65. Thiel A, Heiss WD. Imaging of microglia activation in stroke. Stroke 2011; 42(2): 507-12.
66. Taylor RA, Sansing LH. Microglial responses after ischemic stroke and intracerebral hemorrhage. Clin Dev Immunol 2013; 2013: 746068.
67. Lee Y, Lee SR, Choi SS, Yeo HG, Chang KT, Lee HJ. Therapeutically targeting neuroinflammation and microglia after acute ischemic stroke. Biomed Res Int 2014; 2014: 297241.
68. Morrison HW, Filosa JA. A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J Neuroinflammation 2013; 10: 4.
69. Perego C, Fumagalli S, De Simoni MG. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation 2011; 8: 174.
70. Wang SS, Wang YG, Chen HY, Wu ZP, Xie HG. Expression of genes encoding cytokines and corticotropin releasing factor are altered by citalopram in the hypothalamus of post-stroke depression rats. Neuro Endocrinol Lett 2013; 34(8): 773-9.
71. Narantuya D, Nagai A, Sheikh AM, et al. Human microglia transplanted in rat focal ischemia brain induce neuroprotection and behavioral improvement. PLoS One 2010; 5(7): e11746.
72. Denes A, Vidyasagar R, Feng J, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab 2007; 27(12): 1941-53.
73. Sohrabji F, Williams M. Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia. J Neuroendocrinol 2013; 25(11): 1173-81.
74. Kaushal V, Schlichter LC. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008; 28(9): 2221-30.
75. Brambilla R, Couch Y, Lambertsen KL. The effect of stroke on immune function. Mol Cell Neurosci 2013; 53: 26-33.
76. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab 2012; 32(9): 1677-98.
77. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 2008; 14(33): 3574-89.
78. Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B. Interleukin-1beta and tumor necrosis factoralpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 2008; 5: 46.
79. Maddahi A, Kruse LS, Chen QW, Edvinsson L. The role of tumor necrosis factor-α and TNF-α receptors in cerebral arteries following cerebral ischemia in rat. J Neuroinflammation 2011; 8: 107.
80. Welsh P, Lowe GD, Chalmers J, et al. Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke 2008; 39(8): 2226-30.
81. Greenhalgh AD, Brough D, Robinson EM, Girard S, Rothwell NJ, Allan SM. Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech 2012; 5(6): 823-33.
82. Pardridge WM. Biologic TNFα-inhibitors that cross the human blood-brain barrier. Bioeng Bugs 2010; 1(4): 231-4.
83. Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor α antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflammation 2013; 10(1): 103.
84. Denes A, Wilkinson F, Bigger B, Chu M, Rothwell NJ, Allan SM. Central and haematopoietic interleukin-1 both contribute to ischaemic brain injury in mice. Dis Model Mech 2013; 6(4): 1043-8.
85. Luheshi NM, Kovács KJ, Lopez-Castejon G, Brough D, Denes A. Interleukin-1α expression precedes IL-1β after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J Neuroinflammation 2011; 8: 186.
86. Summers L, Kangwantas K, Rodriguez-Grande B, et al. Activation of brain endothelial cells by interleukin-1 is regulated by the extracellular matrix after acute brain injury. Mol Cell Neurosci 2013; 57: 93-103.
87. Pradillo JM, Denes A, Greenhalgh AD, et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012; 32(9): 1810-9.
88. Yang YF, Chen Z, Hu SL, et al. Interleukin-1 receptor associated kinases-1/4 inhibition protects against acute hypoxia/ischemiainduced neuronal injury in vivo and in vitro. Neuroscience 2011; 196: 25-34.
89. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Proinflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008; 41(16-17): 1330-4.
90. Zeng L, Wang Y, Liu J, et al. Pro-inflammatory cytokine network in peripheral inflammation response to cerebral ischemia. Neurosci Lett 2013; 548: 4-9.
91. Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci 2014; 15(2): 84-97.
92. Fann DY, Lee SY, Manzanero S, Chunduri P, Sobey CG, Arumugam TV. Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res Rev 2013; 12(4): 941-66.
93. Mohamed IN, Ishrat T, Fagan SC, El-Remessy AB. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxid Redox Signal 2015; 22(13): 1188-206.
94. Yang F, Wang Z, Wei X, et al. NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab 2014; 34(4): 660-7.
95. Stone TW, Forrest CM, Darlington LG. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J 2012; 279(8): 1386-97.
96. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 2007; 26(8): 2211-21.
97. Brouns R, Verkerk R, Aerts T, et al. The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke. Neurochem Res 2010; 35(9): 1315-22.
98. Mo X, Pi L, Yang J, Xiang Z, Tang A. Serum indoleamine 2,3- dioxygenase and kynurenine aminotransferase enzyme activity in patients with ischemic stroke. J Clin Neurosci 2014; 21(3): 482-6.
99. Ormstad H, Verkerk R, Aass HC, Amthor KF, Sandvik L. Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke. J Mol Neurosci 2013; 51(3): 893-902.
100. Ormstad H, Verkerk R, Amthor KF, Sandvik L. Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke. J Mol Neurosci 2014; 54(2): 181-7.
101. Bensimon K, Herrmann N, Swardfager W, et al. Kynurenine and depressive symptoms in a poststroke population. Neuropsychiatr Dis Treat 2014; 10: 1827-35.
102. Gold AB, Herrmann N, Swardfager W, et al. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 2011; 8: 17.
103. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
104. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10(4): 287-333.
105. Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. J Clin Psychiatry 2006; 67(8): 1232-9.
106. Taves S, Berta T, Chen G, Ji RR. Microglia and spinal cord synaptic plasticity in persistent pain. Neural Plast 2013; 2013: 753656.
107. Radu BM, Bramanti P, Osculati F, et al. Neurovascular unit in chronic pain. Mediat Inflamm 2013; 2013: 648268.
108. Beggs S, Liu XJ, Kwan C, Salter MW. Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain 2010; 6: 74.
109. Lim TK, Shi XQ, Martin HC, et al. Blood-nerve barrier dysfunction contributes to the generation of neuropathic pain and allows targeting of injured nerves for pain relief. Pain 2014; 155(5): 954-67.
110. DosSantos MF, Holanda-Afonso RC, Lima RL, DaSilva AF, Moura-Neto V. The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 2014; 8: 302.
111. Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol 2005; 289(2): H738-43.
112. Blom JM, Benatti C, Alboni S, et al. Early postnatal chronic inflammation produces long-term changes in pain behavior and Nmethyl-D-aspartate receptor subtype gene expression in the central nervous system of adult mice. J Neurosci Res 2006; 84(8): 1789-98.
113. Benatti C, Alboni S, Capone G, et al. Early neonatal inflammation affects adult pain reactivity and anxiety related traits in mice: genetic background counts. Int J Dev Neurosci 2009; 27(7): 661-8.
114. Shi M, Wang JY, Luo F. Depression shows divergent effects on evoked and spontaneous pain behaviors in rats. J Pain 2010; 11(3): 219-29.
115. McCaffrey G, Seelbach MJ, Staatz WD, et al. Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia. J Neurochem 2008; 106(6): 2395-409.
116. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev 2014; 66(1): 80-101.
117. del Rey A, Wolff C, Wildmann J, et al. Disrupted brain-immune system-joint communication during experimental arthritis. Arthritis Rheum 2008; 58(10): 3090-9.
118. Del Rey A, Wolff C, Wildmann J, Randolf A, Straub RH, Besedovsky HO. When immune-neuro-endocrine interactions are disrupted: experimentally induced arthritis as an example. Neuroimmunomodulation 2010; 17(3): 165-8.
119. Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev 2014; 47: 154-64.
120. Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth 2013; 111(1): 26-37.
121. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol 2008; 21(5): 570-9.
122. Vallejo R, Tilley DM, Vogel L, Benyamin R. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract 2010; 10(3): 167-84.
123. Takeda K, Muramatsu M, Chikuma T, Kato T. Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain. J Mol Neurosci 2009; 39(3): 380-90.
124. LeBlanc BW, Zerah ML, Kadasi LM, Chai N, Saab CY. Minocycline injection in the ventral posterolateral thalamus reverses microglial reactivity and thermal hyperalgesia secondary to sciatic neuropathy. Neurosci Lett 2011; 498(2): 138-42.
125. Burke NN, Geoghegan E, Kerr DM, Moriarty O, Finn DP, Roche M. Altered neuropathic pain behaviour in a rat model of depression is associated with changes in inflammatory gene expression in the amygdala. Genes Brain Behav 2013; 12(7): 705-13.
126. Burke NN, Llorente R, Marco EM, et al. Maternal deprivation is associated with sex-dependent alterations in nociceptive behavior and neuroinflammatory mediators in the rat following peripheral nerve injury. J Pain 2013; 14(10): 1173-84.
127. Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004; 20(2): 467-73.
128. Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. Brain 2015; 138(Pt 3): 604-15.
129. Hernstadt H, Wang S, Lim G, Mao J. Spinal translocator protein (TSPO) modulates pain behavior in rats with CFA-induced monoarthritis. Brain Res 2009; 1286: 42-52.
130. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glialneuronal interactions contribute to descending pain facilitation. J Neurosci 2008; 28(42): 10482-95.
131. Setiawan E, Wilson AA, Mizrahi R, et al. Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry. 2015; 72(3): 268-75.
132. Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 2015; 96(Pt A): 70-82.
133. Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008; 195(1-2): 157-63.
134. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011; 36(12): 2452-9.
135. Kraychete DC, Sakata RK, Issy AM, Bacellar O, Santos-Jesus R, Carvalho EM. Serum cytokine levels in patients with chronic low back pain due to herniated disc: analytical cross-sectional study. Sao Paulo Med J 2010; 128(5): 259-62.
136. Zhao MG, Ko SW, Wu LJ, et al. Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. J Neurosci 2006; 26(35): 8923-30.
137. Chen J, Song Y, Yang J, et al. The contribution of TNF-α in the amygdala to anxiety in mice with persistent inflammatory pain. Neurosci Lett 2013; 541: 275-80.
138. Benatti C, Alboni S, Montanari C, et al. Central effects of a local inflammation in three commonly used mouse strains with a different anxious phenotype. Behav Brain Res 2011; 224(1): 23-34.
139. Xie W, Luo S, Xuan H, et al. Betamethasone affects cerebral expressions of NF-kappaB and cytokines that correlate with pain behavior in a rat model of neuropathy. Ann Clin Lab Sci 2006; 36(1): 39-46.
140. Apkarian AV, Lavarello S, Randolf A, et al. Expression of IL-1beta in supraspinal brain regions in rats with neuropathic pain. Neurosci Lett 2006; 407(2): 176-81.
141. Norman GJ, Karelina K, Zhang N, Walton JC, Morris JS, Devries AC. Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol Psychiatry 2010; 15(4): 404-14.
142. del Rey A, Yau HJ, Randolf A, et al. Chronic neuropathic pain-like behavior correlates with IL-1β expression and disrupts cytokine interactions in the hippocampus. Pain 2011; 152(12): 2827-35.
143. Al-Amin H, Sarkis R, Atweh S, Jabbur S, Saadé N. Chronic dizocilpine or apomorphine and development of neuropathy in two animal models II: effects on brain cytokines and neurotrophins. Exp Neurol 2011; 228(1): 30-40.
144. del Rey A, Apkarian AV, Martina M, Besedovsky HO. Chronic neuropathic pain-like behavior and brain-borne IL-1β. Ann NY Acad Sci 2012; 1262: 101-7.
145. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2009; 60(1): 57-64.
146. Alboni S, Cervia D, Ross B, et al. Mapping of the full length and the truncated interleukin-18 receptor alpha in the mouse brain. J Neuroimmunol 2009; 214(1-2): 43-54.
147. Alboni S, Montanari C, Benatti C, et al. Constitutive and LPSregulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav Immun 2011; 25(3): 483-93.
148. Alboni S, Cervia D, Sugama S, Conti B. Interleukin 18 in the CNS. J Neuroinflammation 2010; 7: 9.
149. Chu YX, Zhang YQ, Zhao ZQ. Involvement of microglia and interleukin-18 in the induction of long-term potentiation of spinal nociceptive responses induced by tetanic sciatic stimulation. Neurosci Bull 2012; 28(1): 49-60.
150. Jeon GS, Park SK, Park SW, Kim DW, Chung CK, Cho SS. Glial expression of interleukin-18 and its receptor after excitotoxic damage in the mouse hippocampus. Neurochem Res 2008; 33(1): 179-84.
151. Miyoshi K, Obata K, Kondo T, Okamura H, Noguchi K. Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci 2008; 28(48): 12775-87.
152. Rojewska E, Popiolek-Barczyk K, Jurga AM, Makuch W, Przewlocka B, Mika J. Involvement of pro- and antinociceptive factors in minocycline analgesia in rat neuropathic pain model. J Neuroimmunol 2014; 277(1-2): 57-66.
153. Cordero MD, Alcocer-Gómez E, Culic O, et al. NLRP3 inflammasome is activated in fibromyalgia: the effect of coenzyme Q10. Antioxid Redox Signal 2014; 20(8): 1169-80.
154. Zhang Y, Liu L, Peng YL, et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Ther 2014; 20(2): 119-24.
155. O’Connor JC, André C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009; 29(13): 4200-9.
156. O’Connor JC, Lawson MA, André C, et al. Lipopolysaccharideinduced depressive-like behavior is mediated by indoleamine 2,3- dioxygenase activation in mice. Mol Psychiatry 2009; 14(5): 511-22.
157. Kim H, Chen L, Lim G, et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J Clin Invest 2012; 122(8): 2940-54.
158. Zhou W, Dantzer R, Budac DP, et al. Peripheral indoleamine 2,3- dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice. Brain Behav Immun 2015; 46: 147-53.
159. Alexander GM, Reichenberger E, Peterlin BL, Perreault MJ, Grothusen JR, Schwartzman RJ. Plasma amino acids changes in complex regional pain syndrome. Pain Res Treat 2013; 2013: 742407.
160. Alboni S, Benatti C, Montanari C, Tascedda F, Brunello N. Chronic antidepressant treatments resulted in altered expression of genes involved in inflammation in the rat hypothalamus. Eur J Pharmacol 2013; 721(1-3): 158-67.
161. Burke NN, Finn DP, Roche M. Chronic administration of amitriptyline differentially alters neuropathic pain-related behaviour in the presence and absence of a depressive-like phenotype. Behav Brain Res 2014; 278C: 193-201.
162. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012; 52(1): 6-17.
163. Arakawa S, Shirayama Y, Fujita Y, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 2012; 100(3): 601-6.
164. Miyaoka T, Wake R, Furuya M, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an openlabel study. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37(2): 222-6.
165. Burke NN, Kerr DM, Moriarty O, Finn DP, Roche M. Minocycline modulates neuropathic pain behaviour and cortical M1-M2 microglial gene expression in a rat model of depression. Brain Behav Immun 2014; 42: 147-56.
166. Zanjani TM, Sabetkasaei M, Mosaffa N, Manaheji H, Labibi F, Farokhi B. Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. Eur J Pharmacol 2006; 538(1-3): 66-72.
167. André C, O’Connor JC, Kelley KW, Lestage J, Dantzer R, Castanon N. Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3-dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroimmunol 2008; 200(1-2): 90-9.
168. Willis CL, Brooks TA, Davis TP. Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity? Curr Pharm Des 2008; 14(16): 1625-43.
169. Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine 2014; 42(12): 698-702.
170. Kwon KJ, Lee EJ, Kim MK, et al. Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitusinduced dementia. Neurobiol Dis 2015; 73: 12-23.
171. Hu P, Thinschmidt JS, Yan Y, et al. CNS inflammation and bone marrow neuropathy in type 1 diabetes. Am J Pathol 2013; 183(5): 1608-20.
172. Mastropaolo MD, Evans NP, Byrnes MK, Stevens AM, Robertson JL, Melville SB. Synergy in polymicrobial infections in a mouse model of type 2 diabetes. Infect Immun 2005; 73(9): 6055-63.
173. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41(3): 281-8.
174. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27(3): 813-23.
175. Taguchi A. Vascular factors in diabetes and Alzheimer’s disease. J Alzheimers Dis 2009; 16(4): 859-64.
176. Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008; 299(23): 2751-9.
177. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment. Diabetologia 2006; 49(3): 469-77.
178. Siddiqui S. Depression in type 2 diabetes mellitus--a brief review. Diabetes Metab Syndr 2014; 8(1): 62-5.
179. Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. ScientificWorldJournal 2006; 6: 908-17.
180. Dalla Vestra M, Mussap M, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 Suppl 1: S78-82.
181. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19(3): 433-42.
182. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 2006; 11(3): 226-31.
183. Rivero A, Mora C, Muros M, García J, Herrera H, Navarro-González JF. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 2009; 116(6): 479-92.
184. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56(2): 173-89.
185. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med 2004; 82(8): 510-29.
186. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007; 50(1): 202-11.
187. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. Diabetes 2005; 54(10): 2977-82.
188. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int J Endocrinol 2014; 2014: 674987.
189. Dey A, Hao S, Erion JR, Wosiski-Kuhn M, Stranahan AM. Glucocorticoid sensitization of microglia in a genetic mouse model of obesity and diabetes. J Neuroimmunol 2014; 269(1-2): 20-7.
190. Hwang IK, Choi JH, Nam SM, et al. Activation of microglia and induction of pro-inflammatory cytokines in the hippocampus of type 2 diabetic rats. Neurol Res 2014; 36(9): 824-32.
191. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54(5): 1559-65.
192. Zychowska M, Rojewska E, Kreiner G, Nalepa I, Przewlocka B, Mika J. Minocycline influences the anti-inflammatory interleukins and enhances the effectiveness of morphine under mice diabetic neuropathy. J Neuroimmunol 2013; 262(1-2): 35-45.
193. Garrido-Mesa N, Zarzuelo A, Gálvez J. What is behind the nonantibiotic properties of minocycline? Pharmacol Res 2013; 67(1): 18-30.
194. Mika J, Osikowicz M, Makuch W, Przewlocka B. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur J Pharmacol 2007; 560(2-3): 142-9.
195. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007; 75(3): 327-32.
196. Cieślak M, Wojtczak A. Role of pro-inflammatory cytokines of pancreatic islets and prospects of elaboration of new methods for the diabetes treatment. Acta Biochim Pol 2015; 62(1): 15-21.
197. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93(10): 4065-74.
198. Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 2004; 45(11): 4161-6.
199. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17(4): 314-21.
200. Lewis EC, Dinarello CA. Responses of IL-18- and IL-18 receptordeficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc Natl Acad Sci USA 2006; 103(45): 16852-7.
201. Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB. Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia 2009; 52(10): 2101-8.
202. Altinova AE, Yetkin I, Akbay E, Bukan N, Arslan M. Serum IL-18 levels in patients with type 1 diabetes: relations to metabolic control and microvascular complications. Cytokine 2008; 42(2): 217-21.
203. Dong G, Liang L, Fu J, Zou C. Serum interleukin-18 levels are raised in diabetic ketoacidosis in Chinese children with type 1 diabetes mellitus. Indian Pediatr 2007; 44(10): 732-6.
204. Harms RZ, Yarde DN, Guinn Z, et al. Increased expression of IL-18 in the serum and islets of type 1 diabetics. Mol Immunol 2015; 64(2): 306-12.
205. Katakami N, Kaneto H, Matsuhisa M, et al. Serum interleukin-18 levels are increased and closely associated with various soluble adhesion molecule levels in type 1 diabetic patients. Diabetes Care 2007; 30(1): 159-61.
206. Ryba-Stanisławowska M, Rybarczyk-Kapturska K, Myśliwiec M, Myśliwska J. Elevated levels of serum IL-12 and IL-18 are associated with lower frequencies of CD4(+)CD25 (high)FOXP3 (+) regulatory t cells in young patients with type 1 diabetes. Inflammation 2014; 37(5): 1513-20.
207. Grishman EK, White PC, Savani RC. Toll-like receptors, the NLRP3 inflammasome, and interleukin-1β in the development and progression of type 1 diabetes. Pediatr Res 2012; 71(6): 626-32.
208. Lee HM, Kim JJ, Kim HJ, Shong M, Ku BJ, Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62(1): 194-204.
209. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 2011; 17(2): 179-88.
210. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12(5): 408-15.
211. Sasaki N, Egashira Y, Sanada H. Production of L-tryptophanderived catabolites in hepatocytes from streptozotocin-induced diabetic rats. Eur J Nutr 2009; 48(3): 145-53.
212. Corriere M, Rooparinesingh N, Kalyani RR. Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden. Curr Diab Rep 2013; 13(6): 805-13.
213. Maraschin Je F. Classification of diabetes. Adv Exp Med Biol 2012; 771: 12-9.
214. Chmiel-Perzyńska I, Perzyński A, Urbańska EM. Experimental diabetes mellitus type 1 increases hippocampal content of kynurenic acid in rats. Pharmacol Rep 2014; 66(6): 1134-9.
215. Patterson AD, Bonzo JA, Li F, et al. Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 2011; 286(22): 19511-22.
216. Munipally PK, Agraharm SG, Valavala VK, Gundae S, Turlapati NR. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch Physiol Biochem 2011; 117(5): 254-8.
217. Cai D. Neuroinflammation and neurodegeneration in overnutritioninduced diseases. Trends Endocrinol Metab 2013; 24(1): 40-7.
218. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
219. Ramirez-Avila L, Regan S, Giddy J, et al. Depressive symptoms and their impact on health-seeking behaviors in newly-diagnosed HIV-infected patients in Durban, South Africa. AIDS Behav 2012; 16(8): 2226-35.
220. Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep 2015; 17(1): 530.
221. Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression--a systematic review of interventions. Psychol Health Med 2011; 16(5): 493-527.
222. Chauhan VS, Chaudhury S, Sudarsanan S, Srivastava K. Psychiatric morbidity in asymptomatic human immunodeficiency virus patients. Ind Psychiatry J 2013; 22(2): 125-30.
223. Elenga N, Georger-Sow MT, Messiaen T, et al. Incidence and predictive factors of depression among patients with HIV infection in Guadeloupe: 1988-2009. Int J STD AIDS 2013; 25(8): 559-63.
224. Judd F, Komiti A, Chua P, et al. Nature of depression in patients with HIV/AIDS. Aust N Z J Psychiatry 2005; 39(9): 826-32.
225. Thames AD, Becker BW, Marcotte TD, et al. Depression, cognition, and self-appraisal of functional abilities in HIV: an examination of subjective appraisal versus objective performance. Clin Neuropsychol 2011; 25(2): 224-43.
226. Logie C, Gadalla TM. Meta-analysis of health and demographic correlates of stigma towards people living with HIV. AIDS Care 2009; 21(6): 742-53.
227. Stutterheim SE, Pryor JB, Bos AE, Hoogendijk R, Muris P, Schaalma HP. HIV-related stigma and psychological distress: the harmful effects of specific stigma manifestations in various social settings. AIDS 2009; 23(17): 2353-7.
228. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-84.
229. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 2005; 5(3): 243-51.
230. Patterson S, Moran P, Epel E, et al. Cortisol patterns are associated with T cell activation in HIV. PLoS One 2013; 8(7): e63429.
231. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2(32): 32ra6.
232. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5(10): e203.
233. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200(6): 749-59.
234. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434(7037): 1148-52.
235. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200(6): 761-70.
236. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008; 112(7): 2826-35.
237. Ellis CL, Ma ZM, Mann SK, et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J Acquir Immune Defic Syndr 2011; 57(5): 363-70.
238. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 2009; 58(2): 220-7.
239. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci USA 2009; 106(16): 6718-23.
240. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 2008; 82(1): 538-45.
241. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5(193): 193ra91.
242. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010; 24(9): 1281-90.
243. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39(4): 633-45.
244. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197(1): 126-33.
245. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12(12): 1365-71.
246. Jiang W, Lederman MM, Hunt P, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199(8): 1177-85.
247. d’Ettorre G, Paiardini M, Zaffiri L, et al. HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res 2011; 9(3): 148-53.
248. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4(10): 762-74.
249. Chattergoon MA, Latanich R, Quinn J, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog 2014; 10(5): e1004082.
250. Kamada AJ, Pontillo A, Guimarães RL, Loureiro P, Crovella S, Brandão LA. NLRP3 polymorphism is associated with protection against human T-lymphotropic virus 1 infection. Mem Inst Oswaldo Cruz 2014; 109(7): 960-3.
251. Hirao LA, Grishina I, Bourry O, et al. Early mucosal sensing of SIV infection by paneth cells induces IL-1β production and initiates gut epithelial disruption. PLoS Pathog 2014; 10(8): e1004311.
252. Guo H, Gao J, Taxman DJ, Ting JP, Su L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J Biol Chem 2014; 289(31): 21716-26.
253. Hernandez JC, Latz E, Urcuqui-Inchima S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology 2014; 57(1): 36-42.
254. Pontillo A, Silva LT, Oshiro TM, Finazzo C, Crovella S, Duarte AJ. HIV-1 induces NALP3-inflammasome expression and interleukin-1β secretion in dendritic cells from healthy individuals but not from HIV-positive patients. AIDS 2012; 26(1): 11-8.
255. Iannello A, Boulassel MR, Samarani S, et al. HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication. J Infect Dis 2010; 201(4): 608-17.
256. Nasi M, Alboni S, Pinti M, et al. Successful treatment of HIV-1 infection increases the expression of a novel, short transcript for IL-18 receptor α chain. J Acquir Immune Defic Syndr 2014; 67(3): 254-7.
257. Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD. HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction. J Cereb Blood Flow Metab 2008; 28(4): 697-711.
258. Dohgu S, Fleegal-DeMotta MA, Banks WA. Lipopolysaccharideenhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by luminal microvessel IL-6 and GM-CSF. J Neuroinflammation 2011; 8: 167.
259. Dohgu S, Banks WA. Brain pericytes increase the lipopolysaccharide-enhanced transcytosis of HIV-1 free virus across the in vitro blood-brain barrier: evidence for cytokinemediated pericyte-endothelial cell crosstalk. Fluids Barriers CNS 2013; 10(1): 23.
260. Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun 2015; 45: 1-12.
261. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. J Neuroimmune Pharmacol 2006; 1(2): 138-51.
262. Owe-Larsson B, Säll L, Salamon E, Allgulander C. HIV infection and psychiatric illness. Afr J Psychiatry 2009; 12(2): 115-28.
263. Schwartz L, Civitello L, Dunn-Pirio A, et al. Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J Neurovirol 2007; 13(3): 274-83.
264. Nakagawa S, Castro V, Toborek M. Infection of human pericytes by HIV-1 disrupts the integrity of the blood-brain barrier. J Cell Mol Med 2012; 16(12): 2950-7.
265. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011; 1399: 96-115.
266. Toborek M, Lee YW, Flora G, et al. Mechanisms of the bloodbrain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005; 25(1): 181-99.
267. Huang Y, Zhao L, Jia B, et al. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci 2011; 31(42): 15195-204.
268. Zhao J, Lopez AL, Erichsen D, et al. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J Neurochem 2004; 88(1): 169-80.
269. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2005; 2: 16.
270. Cheung R, Ravyn V, Wang L, Ptasznik A, Collman RG. Signaling mechanism of HIV-1 gp120 and virion-induced IL-1beta release in primary human macrophages. J Immunol 2008; 180(10): 6675-84.
271. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005; 5(8): 629-40.
272. Chang SL, Connaghan KP, Wei Y, Li MD. NeuroHIV and use of addictive substances. Int Rev Neurobiol 2014; 118: 403-40.
273. Potula R, Poluektova L, Knipe B, et al. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005; 106(7): 2382-90.
274. Purohit V, Rapaka R, Shurtleff D. Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 2011; 44(1): 102-10.
275. Ellis RJ, Croteau D, Hong S. The Textbook of Geriatric Neurology. Upper Saddle River, NJ: Wiley & Sons Inc; 2014.
276. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64(6): 529-36.
277. Del Guerra FB, Fonseca JL, Figueiredo VM, Ziff EB, Konkiewitz EC. Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. J Neurovirol 2013; 19(4): 314-27.
278. Fox HS, Gendelman HE. Commentary: Animal models of neuroAIDS. J Neuroimmune Pharmacol 2012; 7(2): 301-5.